Circulogene Theranostics

Executive Summary

Circulogene Theranostics is a privately held molecular diagnostics company based in Birmingham, Alabama, specializing in comprehensive genomic profiling (CGP) of solid tumors through liquid biopsy. The company’s innovative approach analyzes circulating tumor DNA (ctDNA) and RNA (ctRNA) to guide personalized cancer treatment, offering tests such as OncoGenDx (tissue and plasma assays) and the AI-driven LungLifeAI test for assessing indeterminate pulmonary nodules. Founded in 2015, Circulogene operates in the rapidly growing liquid biopsy market, which is expected to expand as non-invasive cancer detection and monitoring gain adoption. The company differentiates itself through its dual-analyte (DNA+RNA) platform and integration of artificial intelligence for enhanced diagnostic accuracy. Despite being private without disclosed funding or valuation, the company's presence in the competitive diagnostics space suggests ongoing efforts to secure partnerships, regulatory clearances, and clinical validations to drive commercial growth. Circulogene faces significant competition from established players like Guardant Health and Foundation Medicine, but its focus on comprehensive genomic profiling and AI-enabled interpretation could carve out a niche in early detection and therapy selection. The company’s near-term success hinges on validating its tests in large clinical studies, expanding reimbursement coverage, and forming strategic alliances with pharmaceutical firms for companion diagnostics. If it can demonstrate superior sensitivity and specificity in detecting actionable mutations, Circulogene could become a key player in precision oncology. However, as a private entity with limited public information, progress updates and catalyst execution remain uncertain.

Upcoming Catalysts (preview)

• Q3 2026FDA Clearance or CE Mark for OncoGenDx Liquid Biopsy Test60% success
• Q4 2026Strategic Partnership with Major Pharma for Companion Diagnostic Development55% success
• Q2 2026Publication of Clinical Validation Data for LungLifeAI in High-Impact Journal50% success